IBD therapeutics: what is in the pipeline?
Frontline Gastroenterol
; 13(e1): e35-e43, 2022.
Article
in English
| MEDLINE | ID: covidwho-1902037
ABSTRACT
Inflammatory bowel disease (IBD) is an idiopathic long-term relapsing and remitting disorder including ulcerative colitis and Crohn's disease. The aim of therapy is to induce and maintain remission. Anti-TNF therapies dramatically improved clinical outcomes but primary failure or secondary loss is a common problem as well as potential side effects potentially limiting efficacy and long-term use. The advent of new targeted agents with the potential for greater safety is welcomed in IBD and offers the potential for different agents as the disease becomes refractory or even combination therapies to maximise effectiveness without compromising safety in the future. More data are required to understand the best positioning in pathways and longer-term safety effects.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Language:
English
Journal:
Frontline Gastroenterol
Year:
2022
Document Type:
Article
Affiliation country:
Flgastro-2022-102130
Similar
MEDLINE
...
LILACS
LIS